Fenwick Represents Loxo Oncology, Inc. in $138 Million Follow-On Offering

January 10, 2017

Fenwick & West represented Loxo Oncology, Inc. (NASDAQ: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, in its public offering of 4,450,500 shares of its common stock at a public offering price of $31.00 per share, which included exercise in full by the underwriters of their option to purchase 580,500 additional shares of common stock, for gross proceeds to Loxo Oncology of approximately $138 million. The offering was made pursuant to an effective shelf registration statement previously filed with the SEC.

Morgan Stanley & Co. LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC acted as joint book-running managers of the offering. Stifel, Nicolaus & Company, Inc. acted as lead manager.

The Fenwick transaction team included corporate partners Effie Toshav and Robert A. Freedman and associates Julia Forbess, Jordan Roberts, Can Sun and Shiva Mirzanian.